FindTrial
Sign In

Placebo subcutaneous

BIOLOGICAL7 trials

Sponsors

Eli Lilly and Company, Astellas Pharma Europe B.V., Inmunotek S.L.

Conditions

Allergic AsthmaAllergic RhinoconjunctivitisAsthma, AllergicHealthy SubjectsHealthy VolunteersHouse Dust Mite AllergyPerennial Allergic RhinitisPharmacokinetics of ASP6294

Phase 1

A Study of LY3016859 in Healthy Volunteers
CompletedNCT01545583
Eli Lilly and CompanyHealthy Volunteers
Start: 2012-04-30End: 2012-09-30Updated: 2018-07-19
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects
CompletedNCT02681861
Astellas Pharma Europe B.V.Healthy Subjects, Pharmacokinetics of ASP6294
Start: 2016-01-31End: 2016-12-31Updated: 2017-01-10

Phase 2

A Study for Adults With Plaque Psoriasis
TerminatedNCT01018810
Eli Lilly and CompanyPsoriasis
Start: 2009-12-31End: 2010-08-31Updated: 2011-07-29

Phase 3

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
RecruitingNCT04435990
Inmunotek S.L.Asthma, Allergic, Rhinitis, Allergic, Rhinoconjunctivitis
Start: 2020-10-06End: 2026-12-31Target: 150Updated: 2025-05-13
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
TerminatedNCT04874714
Inmunotek S.L.Allergic Rhinoconjunctivitis, House Dust Mite Allergy, Perennial Allergic Rhinitis +1
Start: 2021-04-30End: 2023-10-09Updated: 2023-12-19
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
RecruitingNCT04898283
Inmunotek S.L.Asthma, Allergic, Rhinitis, Allergic, Rhinoconjunctivitis
Start: 2021-05-31End: 2026-10-31Target: 180Updated: 2025-05-13
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
NCT05400811
Inmunotek S.L.Allergic Asthma, Allergic Rhinoconjunctivitis, House Dust Mite Allergy +1
Start: 2022-12-31End: 2025-07-31Target: 400Updated: 2022-11-18